Trump unveils deal to expand coverage and lower costs on obesity drugs

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to expand coverage and reduce prices ...

Trump’s obesity drug deal: the good, the bad, and the unknown

There’s plenty to like about the lower direct-to-consumer prices the White House negotiated with Eli Lilly and Novo Nordisk. There are also caveats and some unanswered questions.

Ozempic, Wegovy, Mounjaro: Affluent Indians use Western drugs to lose weight gained from Western habits

Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro, which is also used to treat diabetes in a ...
The Economist

A second helping of weight-loss drugs is coming

New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...
ConsumerAffairs

Medicare negotiates new prices for Ozempic and Wegovy

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...
Everyday Health on MSN

Experimental Obesity Drug Could Soon Compete With Wegovy and Zepbound

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...

Novo Nordisk inks collaboration with Emcure, to sell its weightloss and diabetes drug Wegovy

Novo Nordisk partners with Emcure to promote Wegovy, following Eli Lilly's recent collaboration with Cipla for tirzepatide in ...

Trump Unveils 'TrumpRx' Program Slashing Prices of Wegovy and Zepbound

Trump launches "TrumpRx" program to cut prices of Wegovy and Zepbound, making weight-loss drugs more affordable for Americans ...